Medtronic PLC $MDT Shares Purchased by Boston Family Office LLC

Boston Family Office LLC raised its position in Medtronic PLC (NYSE:MDT) by 7.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,312 shares of the medical technology company’s stock after purchasing an additional 1,917 shares during the period. Boston Family Office LLC’s holdings in Medtronic were worth $2,468,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its holdings in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Medtronic during the first quarter worth $680,000. Harbour Investments Inc. grew its position in shares of Medtronic by 6.0% in the first quarter. Harbour Investments Inc. now owns 11,465 shares of the medical technology company’s stock valued at $1,030,000 after purchasing an additional 653 shares during the period. Baker Avenue Asset Management LP grew its position in shares of Medtronic by 3.1% in the first quarter. Baker Avenue Asset Management LP now owns 4,558 shares of the medical technology company’s stock valued at $410,000 after purchasing an additional 136 shares during the period. Finally, TIAA Trust National Association increased its stake in Medtronic by 80.6% in the first quarter. TIAA Trust National Association now owns 12,770 shares of the medical technology company’s stock valued at $1,148,000 after purchasing an additional 5,699 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on MDT shares. Truist Financial raised their price target on Medtronic from $103.00 to $110.00 and gave the stock a “hold” rating in a research note on Thursday, November 20th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the company an “outperform” rating in a report on Wednesday, November 19th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Robert W. Baird increased their price target on shares of Medtronic from $103.00 to $109.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $110.44.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is owned by insiders.

Medtronic Price Performance

Medtronic stock opened at $104.53 on Monday. The firm has a fifty day moving average of $96.06 and a 200-day moving average of $91.71. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $134.00 billion, a P/E ratio of 28.79, a PEG ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the business posted $1.26 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.